Release Date: 2024-06-19

Bone Health and Bone Targeted Therapies for Metastatic Prostate Cancer

Halil Lutfi Canat (Author), Adem Alcin (Author)

Release Date: 2024-06-19

This section provides information about bone health and bone-targeted therapies in metastatic prostate cancer. The most common site of metastasis for prostate cancer is the bone. Treatments used in cancer management can also have adverse effects on bones. Bone-related conditions in metastatic prostate cancer are one of the most important causes of morbidity and mortality. [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inCurrent Management of Metastatic Prostate Cancer
    First Page151
    Last Page160
    DOIhttps://doi.org/10.69860/nobel.9786053359142.15
    Page Count10
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    This section provides information about bone health and bone-targeted therapies in metastatic prostate cancer. The most common site of metastasis for prostate cancer is the bone. Treatments used in cancer management can also have adverse effects on bones. Bone-related conditions in metastatic prostate cancer are one of the most important causes of morbidity and mortality. In bone-targeting treatments, resorption modulators and radiotherapy are the main components. Radionuclide agents are innovative treatments for targeting bones.

    Halil Lutfi Canat (Author)
    MD, Professor of Urology, Başaksehir Cam and Sakura City Hospital
    https://orcid.org/0000-0001-6481-7907
    3Halil Lutfi Canat: Dr. Canat graduated from Istanbul University, Istanbul Faculty of Medicine in 2006. He completed his Urology residency at Istanbul Medeniyet University in 2011 and Andrology fellowship at Istanbul University, Istanbul Faculty of Medicine in 2015. In 2018, he received the title of Associate Professor. Since 2020, Dr Canat has been the founding chief of the Urology Center and director of the Andrology Department at Çam and Sakura City Hospital. In 2024, he received the title of Profesor and his areas of interest are: Andrological and robotic surgery, BPH. Dr. Canat has published over 100 reviewed manuscripts and international abstract books. He is the board member of the Turkish Association of Urology and a member of the Société Internationale d’Urologie, Turkish Andrology Association and Endourology Association.

    Adem Alcin (Author)
    MD, Istanbul Medeniyet University
    https://orcid.org/0000-0002-5026-5168
    3Adem Alcin: Dr. Alcin graduated from Istanbul University, Istanbul Faculty of Medicine in 2019. He is continuing his urology residency at Istanbul Medeniyet University. His areas of interest include urological oncology and endourology. He has participated in various academic studies. He is a member of the Turkish Urological Association with a status of a trainee member.

    • Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate. 2014 Feb;74(2):210-6.

    • Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000 May;31(5):578-83.

    • DiNatale A, Fatatis A. The bone microenvironment in prostate cancer metastasis. Adv Exp Med Biol. 2019;1210:171-184.

    • Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005 Jan 13;352(2):154-64.

    • Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A, Van Poznak C, Aapro M, Jordan K; ESMO Guidelines Committee. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020 Dec;31(12):1650-1663.

    • Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR. Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy. Endocrine. 2015 Nov;50(2):344-54.

    • Hart NH, Newton RU, Tan J, Rantalainen T, Chivers P, Siafarikas A, Nimphius S. Biological basis of bone strength: anatomy, physiology and measurement. J Musculoskelet Neuronal Interact. 2020 Sep 1;20(3):347-371.

    • Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011 Jun;11(6):411-25.

    • Clines GA, Guise TA. Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol. 2004 May;2(5):295-302.

    • Choi SW, Sun AK, Cheung JP, Ho JC. Circulating tumour cells in the prediction of bone metastasis. Cancers (Basel). 2024 Jan 5;16(2):252.

    • Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010 Mar;16(3):133-44.

    • Fang J, Xu Q. Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics. Clin Transl Oncol. 2015 Mar;17(3):173-9.

    • Zhang X, Jiang P, Wang C. The role of prostate-specific antigen in the osteoblastic bone metastasis of prostate cancer: a literature review. Front Oncol. 2023 Sep 7;13:1127637.

    • Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s.

    • Parry MG, Cowling TE, Sujenthiran A, Nossiter J, Berry B, Cathcart P, Clarke NW, Payne H, Aggarwal A, van der Meulen J. Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data. Cancer Epidemiol. 2019 Dec;63:101628.

    • Zajączkowska R, Kocot-Kępska M, Leppert W, Wordliczek J. Bone pain in cancer patients: mechanisms and current treatment. Int J Mol Sci. 2019 Nov 30;20(23):6047.

    • Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F. Bone metastases: an overview. Oncol Rev. 2017 May 9;11(1):321.

    • Hu YC, Lun DX, Wang H. Clinical features of neoplastic pathological fracture in long bones. Chin Med J (Engl). 2012 Sep;125(17):3127-32.

    • Lawton AJ, Lee KA, Cheville AL, Ferrone ML, Rades D, Balboni TA, Abrahm JL. Assessment and management of patients with metastatic spinal cord compression: a multidisciplinary review. J Clin Oncol. 2019 Jan 1;37(1):61-71.

    • Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010 Jul;184(1):162-7.

    • Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J; ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014 Sep;25 Suppl 3:iii124-37.

    • Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikström P. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One. 2011 Apr 28;6(4):e19059.

    • Myint ZW, Momo HD, Otto DE, Yan D, Wang P, Kolesar JM. Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2020 Nov 2;3(11):e2025826.

    • Alibhai SMH, Zukotynski K, Walker-Dilks C, et al; Cancer Care Ontario Genitourinary Cancer Disease Site Group. Bone health and bone-targeted therapies for prostate cancer: a programme in evidence-based care - Cancer Care Ontario Clinical Practice Guideline. Clin Oncol (R Coll Radiol). 2017;29(6):348-355.

    • Gartrell BA, Coleman R, Efstathiou E, et al. Metastatic prostate cancer and the bone: significance and therapeutic options. Eur Urol. 2015;68(5):850-858.

    • O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol. 2015 Aug 28;7(8):202-11.

    • Ozülker T, Küçüköz Uzun A, Ozülker F, Ozpaçac T. Comparison of (18)F-FDG-PET/ CT with (99m)Tc-MDP bone scintigraphy for the detection of bone metastases in cancer patients. Nucl Med Commun. 2010 Jun;31(6):597-603.

    • Heindel W, Gübitz R, Vieth V, Weckesser M, Schober O, Schäfers M. The diagnostic imaging of bone metastases. Dtsch Arztebl Int. 2014 Oct 31;111(44):741-7.

    • Mohseninia N, Zamani-Siahkali N, Harsini S, Divband G, Pirich C, Beheshti M. Bone metastasis in prostate cancer: bone scan versus PET imaging. Semin Nucl Med. 2024 Jan;54(1):97-118.

    • Høiberg M, Nielsen TL, Wraae K, Abrahamsen B, Hagen C, Andersen M, Brixen K. Population-based reference values for bone mineral density in young men. Osteoporos Int. 2007 Nov;18(11):1507-14.

    • Pagnotti GM, Trivedi T, Mohammad KS. Translational strategies to target metastatic bone disease. Cells. 2022 Apr 12;11(8):1309.

    • Jing D, Zhao Q, Zhao Y, Lu X, Feng Y, Zhao B, Zhao X. Management of pain in patients with bone metastases. Front Oncol. 2023 Mar 16;13:1156618.

    • Roviello G, Catalano M, Ottanelli C, Giorgione R, Rossi V, Gambale E, Casadei C, De Giorgi U, Antonuzzo L. Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice. Med Oncol. 2022 Jul 14;39(10):145.

    • Tsukamoto S, Kido A, Tanaka Y, Facchini G, Peta G, Rossi G, Mavrogenis AF. Current overview of treatment for metastatic bone disease. Curr Oncol. 2021 Aug 29;28(5):3347- 3372.

    • Cianferotti L, Bertoldo F, Carini M, Kanis JA, Lapini A, Longo N, Martorana G, Mirone V, Reginster JY, Rizzoli R, Brandi ML. The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget. 2017 May 18;8(43):75646-75663.

    • Hoskin PJ, Hopkins K, Misra V, Holt T, McMenemin R, Dubois D, McKinna F, Foran B, Madhavan K, MacGregor C, Bates A, O’Rourke N, Lester JF, Sevitt T, Roos D, Dixit S, Brown G, Arnott S, Thomas SS, Forsyth S, Beare S, Reczko K, Hackshaw A, Lopes A. Effect of single-fraction vs multifraction radiotherapy on ambulatory status among patients with spinal canal compression from metastatic cancer: The SCORAD randomized clinical trial. JAMA. 2019 Dec 3;322(21):2084-2094.

    • Rich SE, Chow R, Raman S, Liang Zeng K, Lutz S, Lam H, Silva MF, Chow E. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018 Mar;126(3):547-557.

    • Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017 Mar;64(1):52-60.

    • Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzén L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213-23.

    • Cirstoiu C, Cretu B, Iordache S, Popa M, Serban B, Cursaru A. Surgical management options for long-bone metastasis. EFORT Open Rev. 2022 Mar 17;7(3):206-213.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!